Mitzi Krockover, M.D.
LIABILITY

Opinion

Mitzi Krockover, M.D.

Humana's vice president for women's health says the plan's review process worked perfectly. Even so, the other side won $13 million. (Humana is appealing.) The case illustrates that once an issue goes before a jury that has little understanding of the clinical considerations, anything can happen. The real "winners?" Trial lawyers.

The case of Karen Johnson, the Louisville, Ky., woman who sued Humana over payment for a hysterectomy, has generated quite a bit of media attention in recent months.

The details of the case are: Johnson was diagnosed with carcinoma in situ, and her ob/gyn recommended a hysterectomy. Humana, which insured Johnson, disagreed, arguing that conization, a less invasive and less risky procedure, was more appropriate.

Independently, three board-certified experts reviewed the case and supported our position. However, in spite of those opinions, she chose to adhere to her physician's recommendation at her own expense, and then sued Humana. A local jury awarded her $13 million, a decision Humana is now appealing.

Before her hysterectomy, however, Johnson did undergo the conization Humana had approved, based on the recommendations of the external expert reviewers.

Pathology tests confirmed the excision of all the abnormal tissue, again indicating that a hysterectomy was not necessary. If a hysterectomy had been indicated at that point, Humana would, of course, have paid for the surgery.

To me, the Johnson case brings up three important issues. First, there continues to be significant variation in practice despite literature and data (i.e., evidence-based medicine) that support best practices.

For example, studies have shown that 30 to 50 percent of all hysterectomies are unnecessary and that another 10 percent could be avoided with alternate therapies. A procedure that's overutilized and that carries significant risks for the patient is clearly appropriate for review. External reviews by managed health care organizations are just one way that best practices can be communicated and implemented.

Second, patients should be encouraged to understand all of their therapeutic options and the inherent risks and benefits of any procedure so that they can make an informed choice. In this case, the system worked to provide that information — Johnson had the equivalent of a second, third, and fourth opinion.

And finally, litigation will never improve the quality of health care. Considering that 57 percent of all trial judgments go to attorney costs and court fees, and that the appeals process allows cases to drag on for years, the road to quality clearly does not run through the courthouse.

Moreover, litigation raises the cost of health care for all Americans, and every time health costs increase by 1 percent, 300,000 more people lose their health care insurance. Women are especially hard hit because they're more likely to work for small businesses, the first companies that drop coverage when costs increase.

This has a tremendous impact on families as well, especially when women are the sole support of many single-parent households.

In arguing Johnson's case, one of her attorneys said that America needs to "put medicine back in the hands of physicians." I wholeheartedly agree. Physicians -- not juries and trial attorneys — should make medical decisions.

That's why Humana uses outside medical experts in our review process and that's why we spend millions of dollars a year on programs, designed and reviewed by physicians, that result in measurable health improvement of our members.

We are very much in concert with physicians who work hard to advocate the best medicines for their patients. We encourage physicians to get involved in the review process and look for ways to translate best practices to the bedside.

Through cooperation, not litigation, we can work together to improve people's health.

Mitzi Krockover, M.D., is Humana's vice president for women's health.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.